Tesamorelin for visceral fat:
15–20% VAT reduction in 26 weeks.

Visceral fat and subcutaneous fat are two biologically distinct tissues with very different metabolic consequences. Subcutaneous fat is the softer fat directly beneath the skin — the fat you can pinch. It is a relatively inert storage depot that contributes to body weight and appearance but has limited effect on cardiometabolic disease. Visceral fat, by contrast, is the deep abdominal fat that wraps around internal organs (liver, pancreas, intestines). It is metabolically active, inflammatory, and directly linked to insulin resistance, cardiovascular disease, type 2 diabetes, fatty liver disease, and all-cause mortality.

Two people with the same body weight and similar appearance can have dramatically different visceral fat levels and dramatically different cardiometabolic risk profiles. This is why waist circumference — a rough proxy for visceral fat — is a stronger predictor of disease than body weight or body mass index in most populations. Reducing visceral fat specifically, while preserving or modestly increasing lean mass, is the ideal body composition intervention from a disease-prevention standpoint.

Tesamorelin for visceral fat exploits a specific biological asymmetry: visceral adipocytes express higher densities of growth hormone receptors than subcutaneous adipocytes. When tesamorelin triggers the pituitary to release GH in a pulsatile pattern, the released GH binds these receptors preferentially on visceral fat cells, activating hormone-sensitive lipase and driving triglyceride breakdown. Subcutaneous fat, with fewer GH receptors per cell, responds less to the same GH pulse. The result is a selective reduction in visceral adipose tissue with minimal change in subcutaneous fat — the exact body composition shift that matters for disease risk.

The clinical evidence for tesamorelin visceral fat reduction is anchored on two Phase III trials published in the New England Journal of Medicine and a follow-up NAFLD study in JAMA.

Falutz et al. 2007 (NEJM). A 26-week randomized, placebo-controlled, double-blind trial of 412 HIV-infected adults with central adiposity and lipodystrophy. Participants received either 2 mg daily subcutaneous tesamorelin or placebo. At 26 weeks, mean visceral adipose tissue (measured by abdominal CT imaging) decreased by 15.2% in the tesamorelin group and increased by 0.6% in the placebo group — a statistically significant and clinically meaningful difference. Subcutaneous fat showed minimal change in either group, confirming the selective VAT effect.

Falutz et al. 2010 (NEJM). Pooled data from the Phase III trials with a 26-week extension in patients who continued tesamorelin therapy. Visceral fat reduction deepened to approximately 18% at 52 weeks, indicating that the effect continues with ongoing therapy though at a diminishing rate. Patients who crossed over from placebo to tesamorelin at the 26-week point showed VAT reduction trajectories mirroring the original tesamorelin group, confirming the effect is reproducible and causal.

Stanley et al. 2014 (JAMA). A 12-month randomized controlled trial specifically in HIV patients with non-alcoholic fatty liver disease (NAFLD). Daily 2 mg tesamorelin produced a 32% reduction in hepatic fat fraction on MRI measurement — a larger relative effect than on abdominal VAT. This finding established that tesamorelin reduces ectopic visceral fat accumulation in the liver, not just the abdomen, and opened interest in tesamorelin for metabolic-associated steatotic liver disease (MASLD, the renamed NAFLD) in non-HIV populations.

Extension and post-marketing. Pooled safety and efficacy analyses through 2+ years of continuous tesamorelin use show sustained VAT reduction without rebound, no new safety signals, and continued IGF-1 elevation within the physiologic range. See the tesamorelin results timeline for a week-by-week breakdown of when and how the VAT reduction unfolds.

"Belly fat" is the colloquial term for abdominal adiposity — and it overlaps with but is not identical to visceral fat. The belly is a composite of three distinct fat compartments: subcutaneous abdominal fat (under the skin of the abdomen), visceral fat (deep, around internal organs), and a smaller amount of intramuscular fat. When people refer to "belly fat" in everyday language, they usually mean all three together, with visual prominence driven by whichever compartment is largest in their individual body.

Tesamorelin for belly fat works primarily by reducing the visceral component — which in most adults with central obesity is the majority of what gives the abdomen a rounded, protruding appearance, particularly in the upper abdomen above the navel. Because visceral fat sits behind the abdominal wall rather than in front of it, VAT reduction often produces a flatter, less distended abdominal profile even when scale weight changes modestly and subcutaneous fat is largely unchanged.

This is why tesamorelin users often report that their abdomen looks visibly flatter and their waist fits smaller in clothes even when the scale moves only slightly. The tesamorelin belly fat effect is real and measurable — waist circumference decreases by a mean of 2.6 cm over 26 weeks in the Phase III trials — but it comes from a specific mechanism (visceral fat lipolysis) rather than from general body fat loss. Patients who expect tesamorelin for belly fat to deliver the same experience as a GLP-1 agonist weight loss protocol will find the two are different; tesamorelin changes abdominal shape and visceral depot mass more than it changes scale weight or total body fat percentage.

GLP-1 agonists like semaglutide and the newer triple agonist retatrutide produce dramatic weight loss through appetite suppression, slowed gastric emptying, and improved satiety. Their effect on visceral fat specifically is meaningful but less selective than tesamorelin's — GLP-1s reduce both visceral and subcutaneous fat roughly in proportion to total body weight loss, rather than preferentially targeting VAT.

Rough clinical comparison at typical doses:

Semaglutide (2.4 mg). Produces approximately 15% total body weight loss over 68 weeks. Visceral fat reduction tracks total weight loss, so VAT reduction is proportionally similar to overall fat reduction. Waist circumference and visceral fat both decrease, but subcutaneous fat also decreases substantially. See the semaglutide peptide guide for full mechanism and clinical data.

Tirzepatide. A dual GLP-1/GIP agonist producing approximately 22.5% weight loss at maximum dose. Similar pattern to semaglutide — general fat reduction with proportional VAT reduction, not VAT-selective.

Retatrutide. A triple agonist (GLP-1/GIP/glucagon) producing approximately 24% weight loss in Phase II. The glucagon component adds direct metabolic rate elevation and may produce slightly more VAT-selective effects than pure GLP-1 agonists, though clinical data on compartment-specific effects is still emerging. See the retatrutide peptide guide.

Tesamorelin. Selective VAT reduction of 15–20% with minimal subcutaneous fat change. Total weight change is modest (-2 to +1 kg typical). This is a fundamentally different body composition shift than the GLP-1 pattern.

The two classes of compounds are not substitutes — they address different problems. GLP-1s are superior for total weight loss in patients whose primary issue is excess body weight. Tesamorelin is superior for targeted visceral fat reduction in patients whose primary issue is central adiposity with preserved or adequate lean mass. Patients with both issues sometimes use tesamorelin and a GLP-1 agonist together — the mechanisms don't overlap (tesamorelin acts through the GH axis, GLP-1s through appetite and metabolic signaling), so combined use can produce additive body composition benefits, though such combinations warrant clinical supervision.

Tesamorelin's selective VAT reduction effect is most beneficial for patients whose cardiometabolic profile is driven by visceral adiposity rather than general excess body weight. Characteristic features of the ideal tesamorelin for belly fat candidate:

Central adiposity with preserved peripheral fat distribution. A protruding abdomen with relatively preserved leg and arm fat — the classic "apple shape" pattern. Waist-to-hip ratio elevated above 0.95 in men or 0.85 in women is a rough clinical indicator.

Elevated waist circumference relative to weight. Patients who carry a disproportionate amount of their body fat at the waist, particularly above the navel, tend to have VAT-dominant adiposity. Waist circumference above 102 cm (40 inches) in men or 88 cm (35 inches) in women is a standard clinical threshold.

Fatty liver (NAFLD or MASLD). Elevated liver fat on imaging or biopsy suggests ectopic fat accumulation in visceral depots. The Stanley JAMA 2014 data showing 32% liver fat reduction makes tesamorelin particularly relevant for this population.

Insulin resistance with preserved glucose tolerance. Patients with metabolic syndrome who are not yet frankly diabetic often have visceral-dominant adiposity. Tesamorelin addresses the underlying VAT driving the insulin resistance rather than just the downstream glycemic consequences.

Patients with already-adequate weight management. Tesamorelin is not a primary weight-loss tool — it's a body composition optimization tool. Patients who have addressed total body weight through diet and exercise but retain stubborn abdominal visceral fat are ideal candidates. Tesamorelin for belly fat in this population produces the most dramatic visible before-and-after response.

Older adults with age-related central adiposity. Visceral fat accumulation increases with age as GH secretion declines, particularly in postmenopausal women and men over 45. This is a population where restoring pulsatile GH with tesamorelin addresses an underlying physiologic shift rather than correcting a pure lifestyle-driven problem.